Aster Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-444
Closed -$238K – 1184
2026
Q2
$238K Buy
+444
New +$227K 0.05% 381
2026
Q1
– Sell
-11
Closed -$6.41K – 1143
2025
Q4
$6.41K Sell
11
-74
-87% -$37.8K ﹤0.01% 830
2025
Q3
$39K Buy
+85
New +$31.7K 0.02% 545
2025
Q2
– Sell
-2,191
Closed -$748K – 1357
2025
Q1
$748K Buy
+2,191
New +$720K 0.14% 215

Other funds holding MDGL

Aster Capital Management's MDGL Position: Q3 2026 in Review

Aster Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 444 shares — an estimated $238K sold.

Aster Capital Management first reported a position in MDGL in Q1 2025 and held it in 4 quarters. The position peaked at $748K in Q1 2025. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Aster Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Aster Capital Management sold 444 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $238K.
  • Aster Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Aster Capital Management's Madrigal Pharmaceuticals position peaked at $748K in Q1 2025.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.